abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 05일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제120회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Drug delivery with doxorubicin loaded oligonucleotide modified gold nanoparticles for colorectal cancer treatment

등록일
2017년 8월 31일 16시 58분 31초
접수번호
2458
발표코드
MEDI.P-366 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
10월 19일 (목요일) 11:00~12:30
발표형식
포스터
발표분야
Medicinal Chemistry
저자 및
공동저자
Chang-Seuk Lee, SuHwan Yu1, Tae Hyun Kim*
Department of Chemistry, Soonchunhyang University, Korea
1Chemistry, Soonchunhyang University, Korea

In this study, we propose doxorubicin (DOX) loaded oligonucleotides (ONTs) modified gold nanoparticles (AuNP) as a drug delivery system (DDS) for colorectal cancer therapy. DOX is one of representative anti-cancer drug and widely used by many research groups as a chemotherapy agent in the DDS. We utilized AuNPs as drug delivery vehicle, because of the advantages of AuNPs such as simple steps in synthesis, high surface-area-to-volume ratio, and biocompatibility. AuNPs were synthesized to be 13 nm diameter by conventional chemical reduction with citrate stabilizer. The G-C rich ONTs were used both for drug loading sites and AuNPs capping materials. The drug loading capacity of DOX loaded ONTs modified AuNPs (DOA) was represented by drug loading content (LC, w/w%), and drug entrapment efficiency (EE, %). The LC and EE of DOA was calculated as 3.02 and 81, respectively. The SW480 cell line was obtained as targeting system of colorectal cancer therapy. The cytotoxicity effect on SW480 cells treated with DOA was performed at in vitro (MTT assay) and in vivo (tumor-bearing mouse). The cell viability of SW480 that treated with DOA for 24 hours, was 41.77 %. The tumor growth inhibition ratio was represented by treatment-control (T/C) ratio; the T/C ratio was found to be 0.69. Thus, our results suggest the use of DOAs as promising drug delivery systems for colorectal cancer therapy.


상단으로